Tapahtumakalenteri

Dr. Gill obtained his medical degree and Ph.D in immunology from the University of Melbourne, and trained in hematology at St Vincent’s Hospital, the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. In 2008 he moved to the United States, first to pursue a post-doctoral fellowship in cellular therapy at Stanford University, and then in 2011 to the University of Pennsylvania where he is now an associate professor of medicine. Dr. Gill’s clinical practice is in leukaemia and bone marrow transplantation. He has led clinical trials of chimeric antigen receptor (CAR) T cells for chronic and acute leukemias. Dr. Gill’s research laboratory focuses on the interface between adoptive cellular therapy and genetic engineering.

https://www.med.upenn.edu/cci/gilllab

If you would like to have a meeting with Dr. Gill, please contact Satu Mustjoki (satu.mustjoki@helsinki.fi) or Francesca De Lorenzo (francesca.delorenzo@helsinki.fi)

Recent publications:

Gill SI, Vides V, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov MA, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Adv. 2022 Mar 29:bloodadvances.2022007317.

Singh N*, Frey NV*, Engels B*, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL*, Gill S*, Ruella M*. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. 2021 May;27(5):842-850. *equal contribution

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020 Aug;38(8):947-953.

Singh N*, Lee YG*, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S*, Ruella M*. Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer Discov. 2020 Apr;10(4):552-567. *equal contribution

Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018 May 31;173(6):1439-1453.e19.